The Application Study Of Double-function Gd-BOPTA Enhanced MRI On Focal Hepatic Lesions

Part OneStudy of Low Dose Gd-BOPTA Enhanced MRI on Focal Hepatic Lesions: Clinical TrialObjective: To evaluate the efficacy of low-dose Gd-BOPTA enhanced MRI in focal hepatic lesions and compare with standard dose Gd-DTPA enhanced MRI; Meanwhile to observe the adverse events incidence and the change of laboratory examinations before and after Gd-BOPTA administration.Materials and Methods: From June 2002 to October 2003, a total 48 patients with suspected focal hepatic lesions (male 38, female 10) underwent precontrast, contrast enhancement with Gd-DTPA and Gd-BOPTA. Each of 24 patients underwent precontrast MRI, standard dose Gd-DTPA dynamic contrast enhanced (DCE) MRI with SE T1WI, FSE T2WI, FMPSPGR T1WI sequences, then low-dose Gd-BOPTA DCE MRI plus delayed scanning performed in following day. DCE MRI included arterial phase, portal phase and equilibrium phase. Then, delayed scanning was obtained at 60 min with SE T1WI and FMPSPGR T1WI. The other 24 cases received the study in the reverse order. Namely Gd-BOPTA enhanced MRI was done before the Gd-DTPA enhanced MRI. The information on the image quality parameters on all sequences, the adverse events and the results of lab examinations were recorded. Results: The image quality parameter of DCE Gd-BOPTA images was much better than that of precontrast images with significant difference (P<0.05), while in comparison with Gd-DTPA images quality parameter, it has no significant difference (P>0.05), But image quality parameter of delayed phase of Gd-BOPTA-enhancement was much better than that of Gd-DTPA images with significant difference (P<0.05). The lab exams of precontrast and following Gd-BOPTA administration including hepatic, renal function, blood electrolytes, etc showed no significant changes(P>0.05). Side effect incidences of Gd-BOPTA and Gd-DTPA were 8.33% and 4.17% respectively (no significant difference). The most common adverse events observed after Gd-BOPTA administration were transient flushing and heat sensation with no disposal and without any sequelae.Conclusion: Gd-BOPTA is a specific hepatic MRI agent with double-function. The function, efficiency and toxicity, side effects with low dose in the first phase are similar to that of Gd-DTPA. Gd-BOPTA in delayed phase is helpful to improve the detectability of focal hepatic lesions.